Vyro develops oncolytic viruses designed to target CNS tumors, based on pioneering research on the oncolytic properties of the Zika Virus.
Vyro Bio has raised $200K in total funding. The most recent round was Seed. The last funding was announced in January 2025.
Vyro Bio's investors include Vesper Ventures SA.
Vyro Bio is headquartered in São Paulo, Brazil.
Vyro develops oncolytic viruses designed to target CNS tumors, based on pioneering research on the oncolytic properties of the Zika Virus.
Vyro Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vyro Bio — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/vyro-bio. Accessed August 15, 2026.
VCBacked. (2025). Vyro Bio — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/vyro-bio
{{cite web |title=Vyro Bio — Funding & Investors |url=https://www.vcbacked.co/company/vyro-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated